NON-CONFIDENTIAL FIRST CONTACT

Pharmaceutical Partnership Project Brief

A practical template for an initial CMO, CDMO or technology-transfer discussion. This document is designed to help a potential partner state the decision context without disclosing protected technical information.

Boundary before an NDA
Do not include patient information, complete formulas, unpublished dossiers, manufacturing instructions, analytical methods or trade secrets. These items require an agreed NDA, permitted purpose and controlled review plan.

What to include

Topic	Safe first-contact information
1. Organisation and contact	Organisation name, contact person, role, business email and country/region.
2. Requested cooperation model	CMO, CDMO, technology transfer, product registration support, or a preliminary discussion of which model may fit.
3. Dosage form and presentation	For example: sterile lyophilized powder injection, sterile powder injection, terminally sterilized small-volume injection, tablet, capsule, cream or ointment.
4. Target market and project stage	Intended market(s), current stage and the decision that needs to be made next.
5. Public product context	A non-confidential product description, route of administration and presentation, only to the extent permitted for initial screening.
6. Intended timing	Desired discussion timing, key decision milestones and any relevant non-confidential constraints.
7. Specific questions	The two or three questions your team needs answered before deciding whether to enter controlled diligence.

Suggested email subject

Non-confidential pharmaceutical partnership brief - [dosage form] - [target market]

Next step

Send the completed non-confidential brief to **lyq@cjrf.com**. An initial exchange does not confirm product fit, capacity, pricing, regulatory outcome, manufacturing acceptance or any commitment by either party. Detailed technical assessment should occur only under a suitable confidentiality and review arrangement.